Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and metaanalysis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: To prevent the perinatal transmission of hepatitis B virus (HBV) from mother to child, administration of an antiviral agent during pregnancy has been attempted in women who are either hepatitis B e antigen positive or have a high viral load. In this systematic review and meta-analysis with randomized controlled trials, we analyzed the efficacy and safety of tenofovir disoproxil fumarate (TDF) in preventing the perinatal transmission of HBV in pregnant women who have high HBV DNA titers. Methods: Multiple comprehensive databases (PubMed, EMBASE, and Cochrane databases) were searched for studies evaluating the efficacy of TDF for the prevention of perinatal transmission of HBV. Results: Two studies (one open label study and one double blind study) were included and analyzed. Intention-to-treat analysis (527 pregnancies) showed that the preventive effect of TDF was not significant (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.13 to 2.17; p = 0.38, I2 = 81%). However, the per-protocol analysis showed that TDF significantly reduced perinatal transmission (OR, 0.10; 95% CI, 0.01 to 0.77; p = 0.03, I2 = 0%). There was no significant difference between the TDF group and the control group with respect to maternal and fetal safety outcomes. Conclusions: In pregnant women who have high HBV DNA titers, TDF can reduce the perinatal transmission from mother to child without significant adverse events.
Abstract
Background/Aims: To prevent the perinatal transmission of hepatitis B virus (HBV) from mother to child, administration of an antiviral agent during pregnancy has been attempted in women who are either hepatitis B e antigen positive or have a high viral load. In this systematic review and meta-analysis with randomized controlled trials, we analyzed the efficacy and safety of tenofovir disoproxil fumarate (TDF) in preventing the perinatal transmission of HBV in pregnant women who have high HBV DNA titers. Methods: Multiple comprehensive databases (PubMed, EMBASE, and Cochrane databases) were searched for studies evaluating the efficacy of TDF for the prevention of perinatal transmission of HBV. Results: Two studies (one open label study and one double blind study) were included and analyzed. Intention-to-treat analysis (527 pregnancies) showed that the preventive effect of TDF was not significant (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.13 to 2.17; p = 0.38, I2 = 81%). However, the per-protocol analysis showed that TDF significantly reduced perinatal transmission (OR, 0.10; 95% CI, 0.01 to 0.77; p = 0.03, I2 = 0%). There was no significant difference between the TDF group and the control group with respect to maternal and fetal safety outcomes. Conclusions: In pregnant women who have high HBV DNA titers, TDF can reduce the perinatal transmission from mother to child without significant adverse events.
참고문헌 (39)
- Stanaway JD, "The global burden of viral hepatitis from 1990 to 2013 : findings from the Global Burden of Disease Study 2013", Lancet, 388, pp.1081~1088 (2016)
- Pan CQ, "Natural history and clinical consequences of hepatitis B virus infection", Int J Med Sci, 2, pp.36~40 (2005)
- "Global Hepatitis Report, 2017" (2017)[URL]
- Jonas MM, "Hepatitis B and pregnancy: an underestimated issue", Liver Int, 29(Suppl 1), pp.133~139 (2009)
- Stevens CE, "Vertical transmission of hepatitis B antigen in Taiwan", N Engl J Med, 292, pp.771~774 (1975)
- Mast EE, "A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States : recommendations of the Advisory Committee on Immunization Practices(ACIP)Part II : immunization of adults", MMWR Recomm Rep, 55, pp.1~33 (2006)
- Chang MH, "Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group", N Engl J Med, 336, pp.1855~1859 (1997)
- Lee C, "Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers", Cochrane Database Syst Rev, 2, pp.CD004790~ (2006)
- Ni YH, "Two decades of universal hepatitis B vaccination in taiwan : impact and implication for future strategies", Gastroenterology, 132, pp.1287~1293 (2007)
- Zou H, "Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers", J Viral Hepat, 19, pp.e18~e25 (2012)
- Xu WM, "Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection : a multicentre, randomized, double-blind, placebo-controlled study", J Viral Hepat, 16, pp.94~103 (2009)
- Han GR, "A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection", J Hepatol, 55, pp.1215~1221 (2011)
- Chen HL, "Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus", Hepatology, 62, pp.375~386 (2015)
- Brown RS Jr, "Antiviral therapy in chronic hepatitis B viral infection during pregnancy : a systematic review and meta-analysis", Hepatology, 63, pp.319~333 (2016)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
- Pan CQ, "Tenofovir to prevent hepatitis B transmission in mothers with high viral load", N Engl J Med, 374, pp.2324~2334 (2016)
- Hyun MH, "Systematic review with meta-analysis : the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus", Aliment Pharmacol Ther, 45, pp.1493~1505 (2017)
- Jourdain G, "Tenofovir versus placebo to prevent perinatal transmission of hepatitis B", N Engl J Med, 378, pp.911~923 (2018)
- Chang MH, "Long-term effects of hepatitis B immunization of infants in preventing liver cancer", Gastroenterology, 151, pp.472~480 (2016)
- Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
- Li XM, "Interruption of HBV intrauterine transmission : a clinical study", World J Gastroenterol, 9, pp.1501~1503 (2003)
- Fischer KP, "Lamivudine resistance in hepatitis B : mechanisms and clinical implications", Drug Resist Updat, 4, pp.118~128 (2001)
- Wang W, "Cost-effectiveness of antiviral therapy during late pregnancy to prevent perinatal transmission of hepatitis B virus", PeerJ, 4, pp.e1709~ (2016)
- Gallant JE, "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients : a 3-year randomized trial", JAMA, 292, pp.191~201 (2004)
- Pintye J, "Maternal tenofovir disoproxil fumarate use during pregnancy is not associated with adverse perinatal outcomes among HIV-infected east African women : a prospective study", J Infect Dis, 216, pp.1561~1568 (2017)
- Wang L, "Safety of tenofovir during pregnancy for the mother and fetus : a systematic review", Clin Infect Dis, 57, pp.1773~1781 (2013)
- Chen HL, "Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV", Gastroenterology, 142, pp.773~781 (2012)
- Pernia S, "The new pregnancy and lactation labeling rule", P T, 41, pp.713~715 (2016)
- "Antiretroviral pregnancy registry interim report" (2019)[URL]
- Siberry GK, "Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy", Clin Infect Dis, 61, pp.996~1003 (2015)
- Stellbrink HJ, "Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults : 48-week results from the ASSERT study", Clin Infect Dis, 51, pp.963~972 (2010)
- Mofenson LM, "Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding", AIDS, 31, pp.213~232 (2017)
- Ransom CE, "Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy", J Acquir Immune Defic Syndr, 64, pp.374~381 (2013)
- Siberry GK, "Safety of tenofovir use during pregnancy : early growth outcomes in HIV-exposed uninfected infants", AIDS, 26, pp.1151~1159 (2012)
- "Cochrane Consumers and Communication Group: meta-analysis" (2016)[URL]
- Crins ND, "Interleukin-2receptor antagonists for pediatric liver transplant recipients : a systematic review and meta-analysis of controlled studies", Pediatr Transplant, 18, pp.839~850 (2014)
- Miller RG, "Riluzole for amyotrophic lateral sclerosis(ALS)", motor neuron disease(MND), 2012, pp.3, CD001447~